Published in PLoS One on January 13, 2012
Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses (2012) 0.89
Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One (2013) 0.89
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci (2014) 0.85
Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One (2013) 0.85
The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol (2012) 0.81
Impact of IL28B genetic variation on HCV-induced liver fibrosis, inflammation, and steatosis: a meta-analysis. PLoS One (2014) 0.81
Impact of host IL28B rs12979860, rs8099917 in interferon responsiveness and advanced liver disease in chronic genotype 3 hepatitis C patients. PLoS One (2014) 0.80
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Springerplus (2016) 0.77
Influence of hepatitis C virus and IL28B genotypes on liver stiffness. PLoS One (2014) 0.76
Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia. J Viral Hepat (2016) 0.75
Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations. Infect Dis (Lond) (2015) 0.75
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med (2002) 36.55
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med (2004) 16.21
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet (2009) 14.16
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology (2010) 7.86
Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 6.96
Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology (2010) 4.58
Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology (2001) 3.80
Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology (2010) 3.26
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol (2011) 3.11
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology (2010) 2.87
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol (2004) 2.81
Hepatitis C--global prevalence (update). Wkly Epidemiol Rec (1999) 2.75
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol (2000) 2.68
Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology (2010) 2.68
Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol (2002) 2.33
Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol (2010) 2.09
Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. J Hepatol (2006) 2.04
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology (2011) 1.68
Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J Virol (2007) 1.61
Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology (2011) 1.53
The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology (2007) 1.50
An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. J Hepatol (2005) 1.46
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol (2011) 1.45
Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology (2006) 1.44
IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology (2011) 1.43
Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol (2010) 1.31
Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol (2002) 1.17
Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus. J Infect Dis (2011) 1.08
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection. J Viral Hepat (2007) 1.07
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12
Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol (2004) 3.92
Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic failure. Gastroenterology (2002) 2.99
Cerebrovascular complications in patients with left-sided infective endocarditis are common: a prospective study using magnetic resonance imaging and neurochemical brain damage markers. Clin Infect Dis (2008) 2.88
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med (2007) 2.85
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study. J Infect Dis (2009) 2.73
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis (2006) 2.55
IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology (2006) 2.54
Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis (2012) 2.39
Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol (2002) 2.33
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol (2002) 2.26
High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum beta-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol (2005) 2.24
Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis (2008) 2.22
The landscape of viral expression and host gene fusion and adaptation in human cancer. Nat Commun (2013) 2.17
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology (2014) 2.17
Antimicrobial resistance predicts death in Tanzanian children with bloodstream infections: a prospective cohort study. BMC Infect Dis (2007) 2.05
Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis (2011) 1.99
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98
Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut (2011) 1.95
Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract (2007) 1.86
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet (2013) 1.83
Incidence rate of community-acquired sepsis among hospitalized acute medical patients-a population-based survey. Crit Care Med (2015) 1.75
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis (2008) 1.69
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS (2011) 1.68
Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis (2006) 1.68
IL-23/IL-17 immunity as a hallmark of Crohn's disease. Inflamm Bowel Dis (2008) 1.66
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Multiplex real-time PCR for detection of respiratory tract infections. J Clin Virol (2008) 1.63
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis (2003) 1.58
A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. BMC Public Health (2006) 1.57
Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS (2011) 1.57
Identification of diarrheagenic Escherichia coli isolated from infants and children in Dar es Salaam, Tanzania. BMC Infect Dis (2007) 1.54
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
Phylogenetic analysis of clinical herpes simplex virus type 1 isolates identified three genetic groups and recombinant viruses. J Virol (2004) 1.51
Histologic activity of childhood chronic hepatitis B related to viremia levels, genotypes, mutations, and epidemiologic factors. J Pediatr Gastroenterol Nutr (2002) 1.50
A randomized comparison of target-controlled propofol infusion and patient-controlled sedation during ERCP. Endoscopy (2013) 1.50
Development of functional gastrointestinal disorders after Giardia lamblia infection. BMC Gastroenterol (2009) 1.48
Excellent booster response 4-6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis (2002) 1.48
Biliary dysplasia in patients with primary sclerosing cholangitis: additional value of DNA ploidity. Liver Int (2011) 1.48
Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS (2012) 1.45
Quantitative analysis of CMV DNA in children the first year after liver transplantation. Pediatr Transplant (2003) 1.43
Direct 16S rRNA gene sequencing from clinical specimens, with special focus on polybacterial samples and interpretation of mixed DNA chromatograms. J Clin Microbiol (2009) 1.43
Surveillance of antimicrobial resistance at a tertiary hospital in Tanzania. BMC Public Health (2004) 1.43
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther (2003) 1.42
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
Calprotectin--a marker of mortality in COPD? Results from a prospective cohort study. COPD (2013) 1.38
Extended spectrum beta-lactamases among Gram-negative bacteria of nosocomial origin from an intensive care unit of a tertiary health facility in Tanzania. BMC Infect Dis (2005) 1.37
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Age specific aetiological agents of diarrhoea in hospitalized children aged less than five years in Dar es Salaam, Tanzania. BMC Pediatr (2011) 1.34
Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care (2006) 1.34
Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis (2005) 1.33
Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract (2007) 1.32
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol (2005) 1.30
Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clin Trials (2006) 1.27
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS (2004) 1.24
Progression of fibrosis in untreated patients with hepatitis C virus infection. Liver (2002) 1.24
Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One (2012) 1.22